Sagar V. Parikh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sagar V. Parikh has a total of 288 co-authors. Here are the top co-authors by number of shared publications:
- Sidney H. Kennedy
University of Toronto
9 shared publications - Raymond W. Lam
University of British Columbia
8 shared publications - Roumen Milev
Departments of Psychiatry and Psychology, Queen's University and Providence Care Hospital, Kingston, ON, Canada
6 shared publications Benicio N. Frey
Mood Disorders Program and Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
4 shared publications- Benicio Noronha Frey
McMaster University
4 shared publications - Daniel J. Mueller
University of Toronto
4 shared publications
Latest Publications
- Open Access
- 26 December 2025
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 71 (3) , 185-198
Modulation of Brain Temporal Complexity During Treatment for Depression: A CAN-BIND-1 Study Report: Modulation de la complexité temporelle du cerveau pendant le traitement de la dépression: rapport de l’étude CAN-BIND-1
Objectives: Current pharmacological antidepressant treatments suffer from low remission rates and slow initiation of therapeutic effects. In addition, the development of new antidepressant treatments is confounded by the lack of consensus on efficient and valid neurophysiological targets. Temporal complexity is an alternative measure of dynamic brain activity that estimates brain signal variability at several timescales. It can be easily extracted from non-invasive brain recordings and provides new insights into pathophysiological mechanisms. We aim to assess the potential of brain temporal complexity as a novel neuromarker to predict the effectiveness of antidepressant treatments. Method: We measured longitudinal changes in temporal complexity of electroencephalography signals in patients undergoing 8 weeks of escitalopram treatment through a Canadian Biomarker Integration Network in Depression (CAN-BIND) trial. Results: As early as 2 weeks after the start of treatment, reduction of complexity in fine timescales was associated with improvement in depressive symptoms. After 8 weeks of treatment, the treatment-related effect shifted towards an increase in coarse timescale complexity, linked to symptom improvement. Conclusions: These results suggest a relative shift away from local, segregated information processing, measured by complexity at fine timescales, in the short term, potentially in favour of a higher long-range communication across networks, as indicated by higher complexity measures at coarse timescales in the long term. Further research into the modulation of multiscale temporal complexity by antidepressant treatments could open new possibilities for faster-acting and more efficient treatments.
- 26 December 2025
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 71 (3) , 185-198
Open AccessModulation of Brain Temporal Complexity During Treatment for Depression: A CAN-BIND-1 Study Report: Modulation de la complexité temporelle du cerveau pendant le traitement de la dépression: rapport de l’étude CAN-BIND-1
Objectives: Current pharmacological antidepressant treatments suffer from low remission rates and slow initiation of therapeutic effects. In addition, the development of new antidepressant treatments is confounded by the lack of consensus on efficient and valid neurophysiological targets. Temporal complexity is an alternative measure of dynamic brain activity that estimates brain signal variability at several timescales. It can be easily extracted from non-invasive brain recordings and provides new insights into pathophysiological mechanisms. We aim to assess the potential of brain temporal complexity as a novel neuromarker to predict the effectiveness of antidepressant treatments. Method: We measured longitudinal changes in temporal complexity of electroencephalography signals in patients undergoing 8 weeks of escitalopram treatment through a Canadian Biomarker Integration Network in Depression (CAN-BIND) trial. Results: As early as 2 weeks after the start of treatment, reduction of complexity in fine timescales was associated with improvement in depressive symptoms. After 8 weeks of treatment, the treatment-related effect shifted towards an increase in coarse timescale complexity, linked to symptom improvement. Conclusions: These results suggest a relative shift away from local, segregated information processing, measured by complexity at fine timescales, in the short term, potentially in favour of a higher long-range communication across networks, as indicated by higher complexity measures at coarse timescales in the long term. Further research into the modulation of multiscale temporal complexity by antidepressant treatments could open new possibilities for faster-acting and more efficient treatments.
- Open Access
A Chatbot for the Management of Bipolar Disorder: Using Retrieval-Augmented Generation with an Open-Weight Large Language Model to Answer Clinical Questions Based on the CANMAT and ISBD 2018 Guidelines for Bipolar Disorder
Objective: Clinical practice guidelines support evidence-based care but are often underused due to complexity, time constraints, and navigation challenges. We investigated whether a conversational agent (chatbot) using an open-weight large language model (LLM) with retrieval-augmented generation (RAG) could provide guideline-consistent answers for bipolar disorder management based on the full 2018 CANMAT and ISBD guidelines, comparing against a system using only the base LLM. Method: We developed a multi-step RAG-based chatbot that retrieves relevant guideline sections and generates responses using Llama 3.3 70B. Twenty-one clinical vignettes spanning all guideline sections were created. Six expert psychiatrists generated queries and were presented with paired responses without labels from two systems: one using the base Llama 3.3 70B model, the other RAG-enhanced. Responses rated guideline consistency on a three-point scale, and were analyzed using mixed-effects ordinal logistic regression. Results: Experts evaluated 126 responses, of which 110 (87.3%) were rated as more or as correct as the baseline system. The RAG system produced 80 answers (63.5%) rated fully consistent with the guidelines versus 24 (19.0%) for baseline, and only 10 answers with major deviation (7.9%) versus 48 (38.1%) for baseline. Ordinal regression showed RAG responses were significantly more likely to be more correct (OR = 9.1, 95% CI 5.3–16.3, p < 0.001), which was consistent across all raters. Preference ratings favored RAG answers in 78.7% of cases. Performance varied by vignette, with some errors in both retrieval and reasoning. Conclusion: The use of RAG with an open-weight model helped produce answers consistent with the CANMAT guidelines across vignettes that required adapting or combining guideline text, suggesting viability of a bipolar guideline chatbot. We identified areas to improve results and evaluation. Future work should explore additional retrieval strategies and LLMs, and test in more naturalistic settings.
Open AccessA Chatbot for the Management of Bipolar Disorder: Using Retrieval-Augmented Generation with an Open-Weight Large Language Model to Answer Clinical Questions Based on the CANMAT and ISBD 2018 Guidelines for Bipolar Disorder
Objective: Clinical practice guidelines support evidence-based care but are often underused due to complexity, time constraints, and navigation challenges. We investigated whether a conversational agent (chatbot) using an open-weight large language model (LLM) with retrieval-augmented generation (RAG) could provide guideline-consistent answers for bipolar disorder management based on the full 2018 CANMAT and ISBD guidelines, comparing against a system using only the base LLM. Method: We developed a multi-step RAG-based chatbot that retrieves relevant guideline sections and generates responses using Llama 3.3 70B. Twenty-one clinical vignettes spanning all guideline sections were created. Six expert psychiatrists generated queries and were presented with paired responses without labels from two systems: one using the base Llama 3.3 70B model, the other RAG-enhanced. Responses rated guideline consistency on a three-point scale, and were analyzed using mixed-effects ordinal logistic regression. Results: Experts evaluated 126 responses, of which 110 (87.3%) were rated as more or as correct as the baseline system. The RAG system produced 80 answers (63.5%) rated fully consistent with the guidelines versus 24 (19.0%) for baseline, and only 10 answers with major deviation (7.9%) versus 48 (38.1%) for baseline. Ordinal regression showed RAG responses were significantly more likely to be more correct (OR = 9.1, 95% CI 5.3–16.3, p < 0.001), which was consistent across all raters. Preference ratings favored RAG answers in 78.7% of cases. Performance varied by vignette, with some errors in both retrieval and reasoning. Conclusion: The use of RAG with an open-weight model helped produce answers consistent with the CANMAT guidelines across vignettes that required adapting or combining guideline text, suggesting viability of a bipolar guideline chatbot. We identified areas to improve results and evaluation. Future work should explore additional retrieval strategies and LLMs, and test in more naturalistic settings.
- Open Access
- 18 November 2025
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 71 (5) , 346-358
The Canadian Network for Mood and Anxiety Treatments Task Force Recommendations for the Use of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplants in Adults With Major Depressive Disorder: Recommandations du Groupe de travail du Réseau canadien pour le traitement des troubles de l’humeur et de l’anxiété (Canadian Network for Mood and Anxiety Treatments, CANMAT) concernant l’utilisation des probiotiques, des prébiotiques, des symbiotiques et de la transplantation de microbiote fécal chez les adultes atteints de trouble dépressif majeur
Background: Approximately one-third of adults with major depressive disorder (MDD) experience limited response or intolerable side effects with existing pharmacotherapies. As such, innovative treatments targeting novel biological pathways are under investigation. One promising area of research is the gut microbiome and its influence on mood through the microbiota–gut–brain axis. Clinical studies have begun evaluating microbiome-targeted interventions such as probiotics, prebiotics, synbiotics, and fecal microbiota transplantation (FMT) as potential treatments for MDD. The Canadian Network for Mood and Anxiety Treatments (CANMAT) convened a task force to evaluate the evidence for microbiome-targeted interventions in adults with MDD and to provide updated clinical recommendations. Methods: A systematic review of randomized controlled trials (RCTs) and meta-analyses was conducted, assessing interventions such as probiotics, prebiotics, synbiotics, and FMT in adults with MDD. The CANMAT methodology was used to determine levels of evidence and treatment line recommendations, which were presented in a question-and-answer format. Results: Twenty-three RCTs and eight meta-analyses were included. Probiotics have been the most extensively studied and have demonstrated modest improvements in depressive symptoms, particularly when used in an adjunctive manner. However, recent high-quality trials yielded mixed results. Evidence for prebiotics and FMT was limited and inconclusive, while synbiotics were assessed in only one small RCT. Most interventions were well tolerated, with few serious adverse events. Conclusions: Probiotics may be cautiously considered as third-line adjunctive treatments for MDD, though findings remain inconsistent. There is currently insufficient evidence to recommend prebiotics, synbiotics, or FMT in clinical practice. Further large-scale, well-controlled trials are needed to clarify efficacy, safety, and optimal patient subgroups.
- 18 November 2025
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 71 (5) , 346-358
Open AccessThe Canadian Network for Mood and Anxiety Treatments Task Force Recommendations for the Use of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplants in Adults With Major Depressive Disorder: Recommandations du Groupe de travail du Réseau canadien pour le traitement des troubles de l’humeur et de l’anxiété (Canadian Network for Mood and Anxiety Treatments, CANMAT) concernant l’utilisation des probiotiques, des prébiotiques, des symbiotiques et de la transplantation de microbiote fécal chez les adultes atteints de trouble dépressif majeur
Background: Approximately one-third of adults with major depressive disorder (MDD) experience limited response or intolerable side effects with existing pharmacotherapies. As such, innovative treatments targeting novel biological pathways are under investigation. One promising area of research is the gut microbiome and its influence on mood through the microbiota–gut–brain axis. Clinical studies have begun evaluating microbiome-targeted interventions such as probiotics, prebiotics, synbiotics, and fecal microbiota transplantation (FMT) as potential treatments for MDD. The Canadian Network for Mood and Anxiety Treatments (CANMAT) convened a task force to evaluate the evidence for microbiome-targeted interventions in adults with MDD and to provide updated clinical recommendations. Methods: A systematic review of randomized controlled trials (RCTs) and meta-analyses was conducted, assessing interventions such as probiotics, prebiotics, synbiotics, and FMT in adults with MDD. The CANMAT methodology was used to determine levels of evidence and treatment line recommendations, which were presented in a question-and-answer format. Results: Twenty-three RCTs and eight meta-analyses were included. Probiotics have been the most extensively studied and have demonstrated modest improvements in depressive symptoms, particularly when used in an adjunctive manner. However, recent high-quality trials yielded mixed results. Evidence for prebiotics and FMT was limited and inconclusive, while synbiotics were assessed in only one small RCT. Most interventions were well tolerated, with few serious adverse events. Conclusions: Probiotics may be cautiously considered as third-line adjunctive treatments for MDD, though findings remain inconsistent. There is currently insufficient evidence to recommend prebiotics, synbiotics, or FMT in clinical practice. Further large-scale, well-controlled trials are needed to clarify efficacy, safety, and optimal patient subgroups.
- Open Access
- 3 September 2025
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 45 (6) , 570-579
Meta-analysis of Response and Remission Outcomes With a Weighted Multigene Pharmacogenomic Test for Adults With Depression
Purpose/Background: Multiple meta-analyses have suggested that pharmacogenomic (PGx) testing may be a valuable tool to improve clinical outcomes for patients with major depressive disorder (MDD) who have failed at least one treatment. However, these meta-analyses included studies with different PGx tests and different trial designs, which produce uncertainty when interpreting results. To investigate the clinical utility of a single weighted multigene PGx test, a meta-analysis was performed for prospective studies utilizing this PGx test in adult patients with MDD. Methods/Procedures: MEDLINE/PubMed and Cochrane [including Embase, clinicaltrials.gov, and International Clinical Trials Registry Platform (ICTRP)] were searched through May 2025 for studies evaluating the impact of pharmacogenomic testing on outcomes for patients with MDD. Using PRISMA guidelines, 243 records were identified, and 6 studies were included that compared PGx-guided care to unguided care in adult patients with MDD, using a single weighted multigene test. Findings/Results: Overall, 3,532 patients were included, with outcomes evaluated at week 8 or week 10. Patients with MDD whose care was guided by the weighted multigene PGx test were 30% more likely to achieve response [relative risk ratio (RR)=1.30, 95% CI: 1.16-1.47, P P <0.001] compared to unguided care. No heterogeneity in outcomes across studies was detected. Implications/Conclusions: Prescribing informed by a weighted multigene PGx test significantly improved response and remission rates among adult patients with MDD who experienced at least 1 prior treatment failure, further demonstrating the clinical utility of weighted multigene PGx testing.
- 3 September 2025
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 45 (6) , 570-579
Open AccessMeta-analysis of Response and Remission Outcomes With a Weighted Multigene Pharmacogenomic Test for Adults With Depression
Purpose/Background: Multiple meta-analyses have suggested that pharmacogenomic (PGx) testing may be a valuable tool to improve clinical outcomes for patients with major depressive disorder (MDD) who have failed at least one treatment. However, these meta-analyses included studies with different PGx tests and different trial designs, which produce uncertainty when interpreting results. To investigate the clinical utility of a single weighted multigene PGx test, a meta-analysis was performed for prospective studies utilizing this PGx test in adult patients with MDD. Methods/Procedures: MEDLINE/PubMed and Cochrane [including Embase, clinicaltrials.gov, and International Clinical Trials Registry Platform (ICTRP)] were searched through May 2025 for studies evaluating the impact of pharmacogenomic testing on outcomes for patients with MDD. Using PRISMA guidelines, 243 records were identified, and 6 studies were included that compared PGx-guided care to unguided care in adult patients with MDD, using a single weighted multigene test. Findings/Results: Overall, 3,532 patients were included, with outcomes evaluated at week 8 or week 10. Patients with MDD whose care was guided by the weighted multigene PGx test were 30% more likely to achieve response [relative risk ratio (RR)=1.30, 95% CI: 1.16-1.47, P P <0.001] compared to unguided care. No heterogeneity in outcomes across studies was detected. Implications/Conclusions: Prescribing informed by a weighted multigene PGx test significantly improved response and remission rates among adult patients with MDD who experienced at least 1 prior treatment failure, further demonstrating the clinical utility of weighted multigene PGx testing.
- 12 August 2025
- Published by MedWorks Media in Psychopharmacology Bulletin
- Vol. 51 (1) , 59-68
Going Virtual During a Pandemic: An Academic Psychiatry Department’s Experience with Telepsychiatry
Background: The novel coronavirus pandemic (COVID-19) led healthcare providers, including mental health providers, across the U.S. to swiftly shift to telemedicine. Objectives: This shift gave our Department of Psychiatry a chance to better understand key challenges and opportunities vis-à-vis virtual mental healthcare. We aimed to obtain provider feedback on the use of telepsychiatry and to learn from the provider perspective about patient experiences with video visits. This information will be used to inform the telemedicine strategy at a systems level within our psychiatry department, our academic health system, as well as the field of telemedicine as a whole. Design and Sample: A 22-item online questionnaire comprising 16 quantitative and six qualitative items was distributed to providers currently using video visits to provide care. Results: A total of 89 mental health providers completed the questionnaire. Outcomes demonstrated that while providers perceive challenges associated with virtual care (e.g., fatigue, technology-related issues, and age-related concerns), they also recognize a number of benefits to themselves and their patients (e.g., convenience and increased access). Overall, provider satisfaction, comfort, and willingness to use telepsychiatry was high. Conclusions: The vast majority of providers adapted quickly to the use of virtual platforms; many endorse advantages that suggest virtual care will continue to be a modality they provide in the future, post-COVID-19. It will be important to continue to evaluate aspects of virtual care that may limit clinical assessments and to optimize use to improve access, convenience, and cost-efficiency of mental healthcare delivery.
- 12 August 2025
- Published by MedWorks Media in Psychopharmacology Bulletin
- Vol. 51 (1) , 59-68
Going Virtual During a Pandemic: An Academic Psychiatry Department’s Experience with Telepsychiatry
Background: The novel coronavirus pandemic (COVID-19) led healthcare providers, including mental health providers, across the U.S. to swiftly shift to telemedicine. Objectives: This shift gave our Department of Psychiatry a chance to better understand key challenges and opportunities vis-à-vis virtual mental healthcare. We aimed to obtain provider feedback on the use of telepsychiatry and to learn from the provider perspective about patient experiences with video visits. This information will be used to inform the telemedicine strategy at a systems level within our psychiatry department, our academic health system, as well as the field of telemedicine as a whole. Design and Sample: A 22-item online questionnaire comprising 16 quantitative and six qualitative items was distributed to providers currently using video visits to provide care. Results: A total of 89 mental health providers completed the questionnaire. Outcomes demonstrated that while providers perceive challenges associated with virtual care (e.g., fatigue, technology-related issues, and age-related concerns), they also recognize a number of benefits to themselves and their patients (e.g., convenience and increased access). Overall, provider satisfaction, comfort, and willingness to use telepsychiatry was high. Conclusions: The vast majority of providers adapted quickly to the use of virtual platforms; many endorse advantages that suggest virtual care will continue to be a modality they provide in the future, post-COVID-19. It will be important to continue to evaluate aspects of virtual care that may limit clinical assessments and to optimize use to improve access, convenience, and cost-efficiency of mental healthcare delivery.
- Open Access
- 31 July 2025
- Published by JMIR Publications Inc. in Journal of Participatory Medicine
- Vol. 17 (1) , e55349
Integrating Patient Choice and Collaborative Care Managers to Implement eHealth Tools in Depression: Self-Report Pilot Study
Background: Improving mental health treatment within the collaborative care model (CoCM) may be achieved by using e-mental health (e-MH) tools and addressing the challenges to their integration. Objective: This study aims to understand how patients select, engage, and use three self-help e-MH tools for depression, and to explore satisfaction with e-MH tools, with a particular emphasis on care manager interactions. Methods: This was a single-center, nonrandomized, preferred assignment study of two cognitive behavioral therapy–based tools (Moodkit and moodgym) and an educational website (the Depression Center Toolkit). The tools were recommended for use in 15-minute sessions 3 times a week, for 6 weeks, coupled with low-intensity care manager coaching. Utilization of e-MH was also captured during an additional 4 weeks without coaching. Self-report outcome measures were gathered at baseline, weekly for 6 weeks, at week 10, and through activities suggested by the tool. Results: The 32 participants enrolled were predominantly female (n=27, 84%), non-Hispanic Caucasian (n=29, 91%), with a mean age of 41.8 (SD 16.1; range 20 to 78) years. Most participants (n=26, 81%) presented with moderate to moderately severe depression (Patient Health Questionnaire-9=11‐19) and a marked level of impairment in different areas of functioning. About 81% (n=26) of the participants initially selected a cognitive behavioral therapy–based tool, and 19% (n=6) selected the educational website. In total, 4 of 32 (12%) participants switched tools within the first week, 6 of 32 (22%) participants dropped out, and one was removed. The remaining 25 active individuals used tools on average 3.0 (SD 2.4) times per week, most time (67%), for 11 to 20 minutes or more at a time. Of the 19 participants reached and surveyed at week 6, 52% (16/31) remained actively engaged with their tools, including 2 users who had switched tools and 8 between 45 and 78 years old. At week 10, about 75% (12/16) of this subgroup were using their tools with no coaching; this represented 49% of the cohort. Satisfaction increased with progressive use of the tool. The care manager’s low-intensity coaching lasted on average 7.9 (SD 3.9) minutes and promoted better understanding and greater use of the tools. Other facilitators to adherence consisted of organization, convenience, ease, accessibility, and privacy policies of the tools, while barriers included time constraints, depressive symptoms, and uncertainty about the efficacy of the tool. Conclusions: Uptake of e-MH tools for depression is feasible and associated with significant user satisfaction in CoCM. Low-intensity care manager coaching is consistent with the CoCM and is associated with uptake and ongoing use of e-MH tools. To our knowledge, this is the first study to leverage the care manager’s proactive outreach to and routine follow-ups with patients toward engagement in self-help digital tools.
- 31 July 2025
- Published by JMIR Publications Inc. in Journal of Participatory Medicine
- Vol. 17 (1) , e55349
Open AccessIntegrating Patient Choice and Collaborative Care Managers to Implement eHealth Tools in Depression: Self-Report Pilot Study
Background: Improving mental health treatment within the collaborative care model (CoCM) may be achieved by using e-mental health (e-MH) tools and addressing the challenges to their integration. Objective: This study aims to understand how patients select, engage, and use three self-help e-MH tools for depression, and to explore satisfaction with e-MH tools, with a particular emphasis on care manager interactions. Methods: This was a single-center, nonrandomized, preferred assignment study of two cognitive behavioral therapy–based tools (Moodkit and moodgym) and an educational website (the Depression Center Toolkit). The tools were recommended for use in 15-minute sessions 3 times a week, for 6 weeks, coupled with low-intensity care manager coaching. Utilization of e-MH was also captured during an additional 4 weeks without coaching. Self-report outcome measures were gathered at baseline, weekly for 6 weeks, at week 10, and through activities suggested by the tool. Results: The 32 participants enrolled were predominantly female (n=27, 84%), non-Hispanic Caucasian (n=29, 91%), with a mean age of 41.8 (SD 16.1; range 20 to 78) years. Most participants (n=26, 81%) presented with moderate to moderately severe depression (Patient Health Questionnaire-9=11‐19) and a marked level of impairment in different areas of functioning. About 81% (n=26) of the participants initially selected a cognitive behavioral therapy–based tool, and 19% (n=6) selected the educational website. In total, 4 of 32 (12%) participants switched tools within the first week, 6 of 32 (22%) participants dropped out, and one was removed. The remaining 25 active individuals used tools on average 3.0 (SD 2.4) times per week, most time (67%), for 11 to 20 minutes or more at a time. Of the 19 participants reached and surveyed at week 6, 52% (16/31) remained actively engaged with their tools, including 2 users who had switched tools and 8 between 45 and 78 years old. At week 10, about 75% (12/16) of this subgroup were using their tools with no coaching; this represented 49% of the cohort. Satisfaction increased with progressive use of the tool. The care manager’s low-intensity coaching lasted on average 7.9 (SD 3.9) minutes and promoted better understanding and greater use of the tools. Other facilitators to adherence consisted of organization, convenience, ease, accessibility, and privacy policies of the tools, while barriers included time constraints, depressive symptoms, and uncertainty about the efficacy of the tool. Conclusions: Uptake of e-MH tools for depression is feasible and associated with significant user satisfaction in CoCM. Low-intensity care manager coaching is consistent with the CoCM and is associated with uptake and ongoing use of e-MH tools. To our knowledge, this is the first study to leverage the care manager’s proactive outreach to and routine follow-ups with patients toward engagement in self-help digital tools.
- 29 March 2025
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 70 (7) , 552-564
Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l’aide des scores de risque polygéniques : Rapport sur l’étude CAN-BIND-1
Objective: The genetic architecture of antidepressant response is poorly understood. This study investigated whether polygenic risk scores (PRSs) for major psychiatric disorders and a personality trait (neuroticism) are associated with antidepressant treatment outcomes. Methods: We analysed 148 participants with major depressive disorder (MDD) from the Canadian Biomarker Integration Network for Depression-1 (CAN-BIND-1) cohort. Participants initially received escitalopram (ESC) monotherapy for 8 weeks. Nonresponders at week 8 received augmentation with aripiprazole (ARI), while responders continued ESC until week 16. Primary outcomes were remission status and symptom improvement measured at weeks 8 and 16. At week 16, post-hoc stratified analyses were performed by treatment arm (ESC-only vs. ESC + ARI). Eleven PRSs derived from genome-wide association studies of psychiatric disorders (e.g., MDD and post-traumatic stress syndrome (PTSD)) and neuroticism, were analysed for associations with these outcomes using logistic and linear regression models. Results: At week 8, a higher PRS for PTSD was nominally associated with a lower probability of remission (odds ratio (OR) = 0.08 [0.014–0.42], empirical p -value = 0.017) and reduced symptom improvement (beta (standard error) = −29.15 (9.76), empirical p -value = 0.019). Similarly, a higher PRS for MDD was nominally associated with decreased remission probability (OR = 0.38 [0.18–0.78], empirical p -value = 0.044). However, none of the results survived multiple testing corrections. At week 16, the stratified analysis for the ESC-only group revealed that a higher PRS for MDD was associated with increased remission probability (empirical p- value = 0.034) and greater symptom improvement (empirical p -value = 0.02). In contrast, higher PRSs for schizophrenia (empirical p -value = 0.013) and attention-deficit hyperactivity disorder (empirical p -value = 0.032) were associated with lower symptom improvement. No significant associations were observed in the ESC + ARI group. Conclusions: These findings suggest that PRSs may influence treatment outcomes, particularly in ESC monotherapy. Replication in larger studies is needed to validate these observations.
- 29 March 2025
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 70 (7) , 552-564
Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l’aide des scores de risque polygéniques : Rapport sur l’étude CAN-BIND-1
Objective: The genetic architecture of antidepressant response is poorly understood. This study investigated whether polygenic risk scores (PRSs) for major psychiatric disorders and a personality trait (neuroticism) are associated with antidepressant treatment outcomes. Methods: We analysed 148 participants with major depressive disorder (MDD) from the Canadian Biomarker Integration Network for Depression-1 (CAN-BIND-1) cohort. Participants initially received escitalopram (ESC) monotherapy for 8 weeks. Nonresponders at week 8 received augmentation with aripiprazole (ARI), while responders continued ESC until week 16. Primary outcomes were remission status and symptom improvement measured at weeks 8 and 16. At week 16, post-hoc stratified analyses were performed by treatment arm (ESC-only vs. ESC + ARI). Eleven PRSs derived from genome-wide association studies of psychiatric disorders (e.g., MDD and post-traumatic stress syndrome (PTSD)) and neuroticism, were analysed for associations with these outcomes using logistic and linear regression models. Results: At week 8, a higher PRS for PTSD was nominally associated with a lower probability of remission (odds ratio (OR) = 0.08 [0.014–0.42], empirical p -value = 0.017) and reduced symptom improvement (beta (standard error) = −29.15 (9.76), empirical p -value = 0.019). Similarly, a higher PRS for MDD was nominally associated with decreased remission probability (OR = 0.38 [0.18–0.78], empirical p -value = 0.044). However, none of the results survived multiple testing corrections. At week 16, the stratified analysis for the ESC-only group revealed that a higher PRS for MDD was associated with increased remission probability (empirical p- value = 0.034) and greater symptom improvement (empirical p -value = 0.02). In contrast, higher PRSs for schizophrenia (empirical p -value = 0.013) and attention-deficit hyperactivity disorder (empirical p -value = 0.032) were associated with lower symptom improvement. No significant associations were observed in the ESC + ARI group. Conclusions: These findings suggest that PRSs may influence treatment outcomes, particularly in ESC monotherapy. Replication in larger studies is needed to validate these observations.
- Top Cited PapersOpen Access
- 12 February 2025
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 70 (6) , 429-489
Canadian Network for Mood and Anxiety Treatments 2024 Clinical Practice Guideline for the Management of Perinatal Mood, Anxiety, and Related Disorders: Guide de pratique 2024 du Canadian Network for Mood and Anxiety Treatments pour le traitement des troubles de l'humeur, des troubles anxieux et des troubles connexes périnatals
Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT) publishes clinical practice guidelines for mood and anxiety disorders. This CANMAT guideline aims to provide comprehensive clinical guidance for the pregnancy and postpartum (perinatal) management of mood, anxiety and related disorders. Methods: CANMAT convened a core editorial group of interdisciplinary academic clinicians and persons with lived experience (PWLE), and 3 advisory panels of PWLE and perinatal health and perinatal mental health clinicians. We searched for systematic reviews of prevention and treatment interventions for perinatal depressive, bipolar, anxiety, obsessive–compulsive and post-traumatic stress disorders (January 2013–October 2023). We prioritized evidence from reviews of randomized controlled trials (RCTs), except for the perinatal safety of medications where reviews of large high-quality observational studies were prioritized due to the absence of RCT data. Targeted searches for individual studies were conducted when systematic reviews were limited or absent. Recommendations were organized by lines of treatment based on CANMAT-defined levels of evidence quality, supplemented by editorial group consensus to balance efficacy, safety, tolerability and feasibility considerations. Results: The guideline covers 10 clinical sections in a question-and-answer format that maps onto the patient care journey: case identification; organization and delivery of care; non-pharmacological (lifestyle, psychosocial, psychological), pharmacological, neuromodulation and complementary and alternative medicine interventions; high-risk clinical situations; and mental health of the father or co-parent. Equity, diversity and inclusion considerations are provided. Conclusions: This guideline's detailed evidence-based recommendations provide clinicians with key information to promote the delivery of effective and safe perinatal mental healthcare. It is hoped that the guideline will serve as a valuable tool for clinicians in Canada and around the world to help optimize clinical outcomes in the area of perinatal mental health. Plain Language Summary Title: The Canadian Network for Mood and Anxiety Treatments 2024 Guideline for Helping People with Mood, Anxiety and Related Disorders During Pregnancy and Postpartum
- 12 February 2025
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 70 (6) , 429-489
Top Cited PapersOpen AccessCanadian Network for Mood and Anxiety Treatments 2024 Clinical Practice Guideline for the Management of Perinatal Mood, Anxiety, and Related Disorders: Guide de pratique 2024 du Canadian Network for Mood and Anxiety Treatments pour le traitement des troubles de l'humeur, des troubles anxieux et des troubles connexes périnatals
Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT) publishes clinical practice guidelines for mood and anxiety disorders. This CANMAT guideline aims to provide comprehensive clinical guidance for the pregnancy and postpartum (perinatal) management of mood, anxiety and related disorders. Methods: CANMAT convened a core editorial group of interdisciplinary academic clinicians and persons with lived experience (PWLE), and 3 advisory panels of PWLE and perinatal health and perinatal mental health clinicians. We searched for systematic reviews of prevention and treatment interventions for perinatal depressive, bipolar, anxiety, obsessive–compulsive and post-traumatic stress disorders (January 2013–October 2023). We prioritized evidence from reviews of randomized controlled trials (RCTs), except for the perinatal safety of medications where reviews of large high-quality observational studies were prioritized due to the absence of RCT data. Targeted searches for individual studies were conducted when systematic reviews were limited or absent. Recommendations were organized by lines of treatment based on CANMAT-defined levels of evidence quality, supplemented by editorial group consensus to balance efficacy, safety, tolerability and feasibility considerations. Results: The guideline covers 10 clinical sections in a question-and-answer format that maps onto the patient care journey: case identification; organization and delivery of care; non-pharmacological (lifestyle, psychosocial, psychological), pharmacological, neuromodulation and complementary and alternative medicine interventions; high-risk clinical situations; and mental health of the father or co-parent. Equity, diversity and inclusion considerations are provided. Conclusions: This guideline's detailed evidence-based recommendations provide clinicians with key information to promote the delivery of effective and safe perinatal mental healthcare. It is hoped that the guideline will serve as a valuable tool for clinicians in Canada and around the world to help optimize clinical outcomes in the area of perinatal mental health. Plain Language Summary Title: The Canadian Network for Mood and Anxiety Treatments 2024 Guideline for Helping People with Mood, Anxiety and Related Disorders During Pregnancy and Postpartum
- 5 September 2024
- Published by Springer Nature
- p. 4989-5009
Managing Workplace Mental Health: Multiple Approaches at Patient, Provider, and Systems Levels
- 5 September 2024
- Published by Springer Nature
- p. 4989-5009
Managing Workplace Mental Health: Multiple Approaches at Patient, Provider, and Systems Levels
- 4 September 2024
- Published by Springer Nature in Academic Psychiatry
- Vol. 49 (2) , 208-209
Enhancing Resident Education and Expanding Care with Group Medical Visits/Shared Medical Appointments
- 4 September 2024
- Published by Springer Nature in Academic Psychiatry
- Vol. 49 (2) , 208-209
Enhancing Resident Education and Expanding Care with Group Medical Visits/Shared Medical Appointments